Showing results (41-50 of 148) with videos related to

Sort By:
Pageof 15
Methods in Molecular Biology (Clifton, N.J.)|August 12, 2010
Rescue of misfolded proteins and stabilization by small moleculesRaymond C Stevens, Javier Sancho, Aurora Martinez
The Spanish Journal of Psychology|October 28, 2010
Managing environmental knowledge through learning processes in Spanish hospitality companiesJuan Gabriel Cegarra-Navarro, Aurora Martinez Martinez
Methods in Molecular Biology (Clifton, N.J.)|October 21, 2018
Early Stage Discovery and Validation of Pharmacological Chaperones for the Correction of Protein Misfolding DiseasesOscar Aubi, Per M Knappskog, Aurora Martinez
Frontiers in Pharmacology|December 16, 2020
Inhibition of Tryptophan Hydroxylases and Monoamine Oxidase-A by the Proton Pump Inhibitor, Omeprazole-In Vitro and In Vivo InvestigationsNibal Betari, Kristoffer Sahlholm, Xavier Morató, et al.
The Journal of Biological Chemistry|August 20, 2002
Phosphorylation and mutations of Ser(16) in human phenylalanine hydroxylase. Kinetic and structural effectsFrederico Faria Miranda, Knut Teigen, Matthías Thórólfsson, et al.
Chemical Communications (Cambridge, England)|February 14, 2015
All-atom lipid bilayer self-assembly with the AMBER and CHARMM lipid force fieldsÅge A Skjevik, Benjamin D Madej, Callum J Dickson, et al.
Proteins|May 12, 2012
A dynamic model of long-range conformational adaptations triggered by nucleotide binding in GroEL-GroESLars Skjaerven, Arturo Muga, Nathalie Reuter, et al.
Expert Opinion on Therapeutic Targets|December 16, 2016
Tyrosine and tryptophan hydroxylases as therapeutic targets in human diseaseKai Waløen, Rune Kleppe, Aurora Martinez, et al.
FEBS Letters|November 26, 2013
Modelling cellular signal communication mediated by phosphorylation dependent interaction with 14-3-3 proteinsRune Kleppe, Sadaf Ghorbani, Aurora Martinez, et al.
Frontiers in Pharmacology|June 4, 2026
SOM3355: a unique pharmacological profile combining VMAT1 inhibition, VMAT2-mediated dopamine modulation, and β1-adrenergic antagonism for the treatment of movement and neuropsychiatric disordersEmily S Turilli-Ghisolfi, Svein Isungset Støve, Oscar Huertas, et al.
Pageof 15